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Chapter 1: Definition and classification of CKD
1.1:DEFINITION OF CKD
1.1.1: CKD is defined as abnormalities of kidney structure or function, present for43 months, with implications for
health. (Not Graded)
1.2: STAGING OF CKD
1.2.1: We recommend that CKD is classified based on cause, GFR category, and albuminuria category (CGA). (1B)
1.2.2: Assign cause of CKD based on presence or absence of systemic disease and the location within the kidney of
observed or presumed pathologic-anatomic findings. (Not Graded)
1.2.3: Assign GFR categories as follows (Not Graded):
1.2.4: Assign albuminuria* categories as follows (Not Graded):
*note that where albuminuria measurement is not available, urine reagent strip results can be substituted (Table 7)
1.3: PREDICTING PROGNOSIS OF CKD
1.3.1: In predicting risk for outcome of CKD, identify the following variables: 1) cause of CKD; 2) GFR category;
3) albuminuria category; 4) other risk factors and comorbid conditions. (Not Graded)
Criteria for CKD (either of the following present for 43 months)
Markers of kidney damage (one or more) Albuminuria (AER Z30mg/24 hours; ACR Z30mg/g [Z3mg/mmol])
Urine sediment abnormalities
Electrolyte and other abnormalities due to tubular disorders
Abnormalities detected by histology
Structural abnormalities detected by imaging
History of kidney transplantation
Decreased GFR GFR o60ml/min/1.73 m2 (GFR categories G3a–G5)
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.
GFR categories in CKD
GFR category GFR (ml/min/1.73 m2) Terms
G1 Z90 Normal or high
G2 60–89 Mildly decreased*
G3a 45–59 Mildly to moderately decreased
G3b 30–44 Moderately to severely decreased
G4 15–29 Severely decreased
G5 o15 Kidney failure
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.
*Relative to young adult level
In the absence of evidence of kidney damage, neither GFR category G1 nor G2 fulfill the criteria for CKD.
Albuminuria categories in CKD
AER
ACR (approximate equivalent)
Category (mg/24 hours) (mg/mmol) (mg/g) Terms
A1 o30 o3 o30 Normal to mildly increased
A2 30-300 3-30 30-300 Moderately increased*
A3 4300 430 4300 Severely increased**
Abbreviations: AER, albumin excretion rate; ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease.
*Relative to young adult level.
**Including nephrotic syndrome (albumin excretion usually 42200mg/24 hours [ACR 42220mg/g; 4220mg/mmol]).
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1.3.2: In people with CKD, use estimated risk of concurrent complications and future outcomes to guide decisions
for testing and treatment for CKD complications. (Not Graded)
1.3.3: In populations with CKD, group GFR and albuminuria categories with similar relative risk for CKD outcomes
into risk categories. (Not Graded)
1.4: EVALUATION OF CKD
1.4.1: Evaluation of chronicity
1.4.1.1: In people with GFR o60ml/min/1.73 m2 (GFR categories G3a-G5) or markers of kidney damage, review
past history and previous measurements to determine duration of kidney disease. (Not Graded)
K If duration is 43 months, CKD is confirmed. Follow recommendations for CKD.
K If duration is not43 months or unclear, CKD is not confirmed. Patients may have CKD or acute kidney
diseases (including AKI) or both and tests should be repeated accordingly.
1.4.2: Evaluation of cause
1.4.2.1: Evaluate the clinical context, including personal and family history, social and environmental factors,
medications, physical examination, laboratory measures, imaging, and pathologic diagnosis to determine
the causes of kidney disease. (Not Graded)
1.4.3: Evaluation of GFR
1.4.3.1: We recommend using serum creatinine and a GFR estimating equation for initial assessment. (1A)
1.4.3.2: We suggest using additional tests (such as cystatin C or a clearance measurement) for confirmatory testing
in specific circumstances when eGFR based on serum creatinine is less accurate. (2B)
1.4.3.3: We recommend that clinicians (1B):
K use a GFR estimating equation to derive GFR from serum creatinine (eGFRcreat) rather than relying on
the serum creatinine concentration alone.
K understand clinical settings in which eGFRcreat is less accurate.
1.4.3.4: We recommend that clinical laboratories should (1B):
K measure serum creatinine using a specific assay with calibration traceable to the international standard reference
materials and minimal bias compared to isotope-dilution mass spectrometry (IDMS) reference methodology.
K report eGFRcreat in addition to the serum creatinine concentration in adults and specify the equation
used whenever reporting eGFRcreat.










































G1 Normal or high ≥90
G2 Mildly decreased 60-89
G3a Mildly to moderately decreased 45-59
G3b Moderately to 
severely decreased 30-44
G4 Severely decreased 15-29
G5 Kidney failure <15
Prognosis of CKD by GFR
 and Albuminuria Categories:
KDIGO 2012
Green: low risk (if no other markers of kidney disease, no CKD); Yellow: moderately increased risk; Orange: high risk; Red, very high risk.
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K report eGFRcreat in adults using the 2009 CKD-EPI creatinine equation. An alternative creatinine-based
GFR estimating equation is acceptable if it has been shown to improve accuracy of GFR estimates
compared to the 2009 CKD-EPI creatinine equation.
When reporting serum creatinine:
K We recommend that serum creatinine concentration be reported and rounded to the nearest whole
number when expressed as standard international units (lmol/l) and rounded to the nearest 100th of a
whole number when expressed as conventional units (mg/dl).
When reporting eGFRcreat:
K We recommend that eGFRcreat should be reported and rounded to the nearest whole number and
relative to a body surface area of 1.73 m2 in adults using the units ml/min/1.73 m2.
K We recommend eGFRcreat levels less than 60ml/min/1.73 m
2 should be reported as ‘‘decreased.’’
1.4.3.5: We suggest measuring cystatin C in adults with eGFRcreat 45–59 ml/min/1.73 m
2 who do not have markers
of kidney damage if confirmation of CKD is required. (2C)
K If eGFRcys/eGFRcreat-cys is also o60ml/min/1.73 m2, the diagnosis of CKD is confirmed.
K If eGFRcys/eGFRcreat-cys is Z60ml/min/1.73 m
2, the diagnosis of CKD is not confirmed.
1.4.3.6: If cystatin C is measured, we suggest that health professionals (2C):
K use a GFR estimating equation to derive GFR from serum cystatin C rather than relying on the serum
cystatin C concentration alone.
K understand clinical settings in which eGFRcys and eGFRcreat-cys are less accurate.
1.4.3.7: We recommend that clinical laboratories that measure cystatin C should (1B):
K measure serum cystatin C using an assay with calibration traceable to the international standard
reference material.
K report eGFR from serum cystatin C in addition to the serum cystatin C concentration in adults and
specify the equation used whenever reporting eGFRcys and eGFRcreat-cys.
K report eGFRcys and eGFRcreat-cys in adults using the 2012 CKD-EPI cystatin C and 2012 CKD-EPI
creatinine-cystatin C equations, respectively, or alternative cystatin C-based GFR estimating
equations if they have been shown to improve accuracy of GFR estimates compared to the 2012
CKD-EPI cystatin C and 2012 CKD-EPI creatinine-cystatin C equations.
When reporting serum cystatin C:
K We recommend reporting serum cystatin C concentration rounded to the nearest 100th of a whole
number when expressed as conventional units (mg/l).
When reporting eGFRcys and eGFRcreat-cys:
K We recommend that eGFRcys and eGFRcreat-cys be reported and rounded to the nearest whole number
and relative to a body surface area of 1.73 m2 in adults using the units ml/min/1.73 m2.
K We recommend eGFRcys and eGFRcreat-cys levels less than 60 ml/min/1.73 m
2 should be reported as
‘‘decreased.’’
1.4.3.8: We suggest measuring GFR using an exogenous filtration marker under circumstances where more
accurate ascertainment of GFR will impact on treatment decisions. (2B)
1.4.4: Evaluation of albuminuria
1.4.4.1: We suggest using the following measurements for initial testing of proteinuria (in descending order of
preference, in all cases an early morning urine sample is preferred) (2B):
1) urine albumin-to-creatinine ratio (ACR);
2) urine protein-to-creatinine ratio (PCR);
3) reagent strip urinalysis for total protein with automated reading;
4) reagent strip urinalysis for total protein with manual reading.
1.4.4.2: We recommend that clinical laboratories report ACR and PCR in untimed urine samples in addition to
albumin concentration or proteinuria concentrations rather than the concentrations alone. (1B)
1.4.4.2.1: The term microalbuminuria should no longer be used by laboratories. (Not Graded)
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1.4.4.3: Clinicians need to understand settings that may affect interpretation of measurements of albuminuria
and order confirmatory tests as indicated (Not Graded):
K Confirm reagent strip positive albuminuria and proteinuria by quantitative laboratory measurement
and express as a ratio to creatinine wherever possible.
K Confirm ACRZ30mg/g (Z3mg/mmol) on a random untimed urine with a subsequent early
morning urine sample.
K If a more accurate estimate of albuminuria or total proteinuria is required, measure albumin
excretion rate or total protein excretion rate in a timed urine sample.
1.4.4.4: If significant non-albumin proteinuria is suspected, use assays for specific urine proteins (e.g., a1-micro-
globulin, monoclonal heavy or light chains, [known in some countries as ‘‘Bence Jones’’ proteins]). (Not Graded)
Chapter 2: Definition, identification, and prediction of
CKD progression
2.1: DEFINITION AND IDENTIFICATION OF CKD PROGRESSION
2.1.1: Assess GFR and albuminuria at least annually in people with CKD. Assess GFR and albuminuria more often
for individuals at higher risk of progression, and/or where measurement will impact therapeutic decisions
(see figure below). (Not Graded)
2.1.2: Recognize that small fluctuations in GFR are common and are not necessarily indicative of progression.
(Not Graded)
2.1.3: Define CKD progression based on one of more of the following (Not Graded):
K Decline in GFR category (Z90 [G1], 60–89 [G2], 45–59 [G3a], 30–44 [G3b], 15–29 [G4],o15 [G5]ml/min/
1.73 m2). A certain drop in eGFR is defined as a drop in GFR category accompanied by a 25% or greater
drop in eGFR from baseline.
K Rapid progression is defined as a sustained decline in eGFR of more than 5ml/min/1.73 m2/yr.
K The confidence in assessing progression is increased with increasing number of serum creatinine
measurements and duration of follow-up.
2.1.4: In people with CKD progression, as defined in Recommendation 2.1.3, review current management, examine
for reversible causes of progression, and consider referral to a specialist. (Not Graded)
Guide to Frequency of Monitoring
(number of times per year) by
GFR and Albuminuria Category 
Persistent albuminuria categories



























G1 Normal or high ≥90 1 if CKD 1 2
G2 Mildly decreased 60–89 1 if CKD 1 2
G3a Mildly to moderately decreased 45–59 1 2 3
G3b Moderately to 
severely decreased
30–44 2 3 3
G4 Severely decreased 15–29 3 3 4+














GFR and albuminuria grid to reflect the risk of progression by intensity of coloring (green, yellow, orange, red, deep red). The numbers in
the boxes are a guide to the frequency of monitoring (number of times per year).
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2.2: PREDICTORS OF PROGRESSION
2.2.1: Identify factors associated with CKD progression to inform prognosis. These include cause of CKD,
level of GFR, level of albuminuria, age, sex, race/ethnicity, elevated BP, hyperglycemia, dyslipidemia,
smoking, obesity, history of cardiovascular disease, ongoing exposure to nephrotoxic agents, and others.
(Not Graded)
Chapter 3: Management of progression and
complications of CKD
3.1: PREVENTION OF CKD PROGRESSION
BP and RAAS interruption
3.1.1: Individualize BP targets and agents according to age, coexistent cardiovascular disease and other comorbidities,
risk of progression of CKD, presence or absence of retinopathy (in CKD patients with diabetes), and tolerance
of treatment as described in the KDIGO 2012 Blood Pressure Guideline. (Not Graded)
3.1.2: Inquire about postural dizziness and check for postural hypotension regularly when treating CKD patients with
BP-lowering drugs. (Not Graded)
3.1.3: Tailor BP treatment regimens in elderly patients with CKD by carefully considering age, comorbidities and
other therapies, with gradual escalation of treatment and close attention to adverse events related to BP
treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and
drug side effects. (Not Graded)
3.1.4: We recommend that in both diabetic and non-diabetic adults with CKD and urine albumin excretiono30mg/
24 hours (or equivalent*) whose office BP is consistently 4140mm Hg systolic or 490mm Hg diastolic be
treated with BP-lowering drugs to maintain a BP that is consistently r140mm Hg systolic and r90mm Hg
diastolic. (1B)
3.1.5: We suggest that in both diabetic and non-diabetic adults with CKD and with urine albumin excretion of
Z30mg/24 hours (or equivalent*) whose office BP is consistently 4130mm Hg systolic or 480mm Hg
diastolic be treated with BP-lowering drugs to maintain a BP that is consistently r130mm Hg systolic and
r80mm Hg diastolic. (2D)
3.1.6: We suggest that an ARB or ACE-I be used in diabetic adults with CKD and urine albumin excretion 30–300mg/
24 hours (or equivalent*). (2D)
3.1.7: We recommend that an ARB or ACE-I be used in both diabetic and non-diabetic adults with CKD and urine
albumin excretion 4300mg/24 hours (or equivalent*). (1B)
3.1.8: There is insufficient evidence to recommend combining an ACE-I with ARBs to prevent progression of CKD.
(Not Graded)
3.1.9: We recommend that in children with CKD, BP-lowering treatment is started when BP is consistently above the
90th percentile for age, sex, and height. (1C)
3.1.10:We suggest that in children with CKD (particularly those with proteinuria), BP is lowered to consistently
achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless
achieving these targets is limited by signs or symptoms of hypotension. (2D)
3.1.11:We suggest that an ARB or ACE-I be used in children with CKD in whom treatment with BP-lowering drugs is
indicated, irrespective of the level of proteinuria. (2D)
*Approximate equivalents for albumin excretion rate per 24 hours—expressed as protein excretion rate per 24 hours, albumin-to-creatinine ratio, protein-to-
creatinine ratio, and protein reagent strip results— are given in Table 7, Chapter 1.
CKD and risk of AKI
3.1.12: We recommend that all people with CKD are considered to be at increased risk of AKI. (1A)
3.1.12.1: In people with CKD, the recommendations detailed in the KDIGO AKI Guideline should be
followed for management of those at risk of AKI during intercurrent illness, or when undergoing
investigation and procedures that are likely to increase the risk of AKI. (Not Graded)
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Protein intake
3.1.13: We suggest lowering protein intake to 0.8 g/kg/day in adults with diabetes (2C) or without diabetes (2B) and
GFR o30ml/min/ 1.73 m2 (GFR categories G4-G5), with appropriate education.
3.1.14: We suggest avoiding high protein intake (41.3 g/kg/day) in adults with CKD at risk of progression. (2C)
Glycemic control
3.1.15: We recommend a target hemoglobin A1c (HbA1c) ofB7.0% (53mmol/mol) to prevent or delay progression of
the microvascular complications of diabetes, including diabetic kidney disease. (1A)
3.1.16: We recommend not treating to an HbA1c target of o7.0% (o53mmol/mol) in patients at risk of
hypoglycemia. (1B)
3.1.17: We suggest that target HbA1c be extended above 7.0% (53mmol/mol) in individuals with comorbidities or
limited life expectancy and risk of hypoglycemia. (2C)
3.1.18: In people with CKD and diabetes, glycemic control should be part of a multifactorial intervention strategy
addressing blood pressure control and cardiovascular risk, promoting the use of angiotensin-converting
enzyme inhibition or angiotensin receptor blockade, statins, and antiplatelet therapy where clinically
indicated. (Not Graded)
Salt intake
3.1.19: We recommend lowering salt intake to o90mmol (o2 g) per day of sodium (corresponding to 5 g of sodium
chloride) in adults, unless contraindicated (see rationale). (1C)
3.1.19.1: We recommend restriction of sodium intake for children with CKD who have hypertension (systolic and/
or diastolic blood pressure495th percentile) or prehypertension (systolic and/or diastolic blood pressure
490th percentile and o95th percentile), following the age-based Recommended Daily Intake. (1C)
3.1.19.2: We recommend supplemental free water and sodium supplements for children with CKD and polyuria to
avoid chronic intravascular depletion and to promote optimal growth. (1C)
Hyperuricemia
3.1.20: There is insufficient evidence to support or refute the use of agents to lower serum uric acid concentrations in
people with CKD and either symptomatic or asymptomatic hyperuricemia in order to delay progression of CKD.
(Not Graded)
Lifestyle
3.1.21: We recommend that people with CKD be encouraged to undertake physical activity compatible with
cardiovascular health and tolerance (aiming for at least 30minutes 5 times per week), achieve a healthy weight
(BMI 20 to 25, according to country specific demographics), and stop smoking. (1D)
Additional dietary advice
3.1.22: We recommend that individuals with CKD receive expert dietary advice and information in the context of an
education program, tailored to severity of CKD and the need to intervene on salt, phosphate, potassium, and
protein intake where indicated. (1B)
3.2: COMPLICATIONS ASSOCIATED WITH LOSS OF KIDNEY FUNCTION
Definition and identification of anemia in CKD
3.2.1: Diagnose anemia in adults and children 415 years with CKD when the Hb concentration is o13.0 g/dl
(o130 g/l) in males and o12.0 g/dl (o120 g/l) in females. (Not Graded)
3.2.2: Diagnose anemia in children with CKD if Hb concentration is o11.0 g/dl (o110 g/l) in children 0.5–5 years,
o11.5 g/dl (115 g/l) in children 5–12 years, and o12.0 g/dl (120 g/l) in children 12-15 years. (Not Graded)
Evaluation of anemia in people with CKD
3.2.3: To identify anemia in people with CKD measure Hb concentration (Not Graded):
K when clinically indicated in people with GFR Z60ml/min/1.73 m2 (GFR categories G1-G2);
K at least annually in people with GFR 30–59ml/min/1.73 m2 (GFR categories G3a-G3b);
K at least twice per year in people with GFRo30ml/min/1.73 m2 (GFR categories G4-G5).
10 Kidney International Supplements (2013) 3, 5–14
summary o f recommendat ion s ta tements
3.3: CKD METABOLIC BONE DISEASE INCLUDING LABORATORY ABNORMALITIES
3.3.1: We recommend measuring serum levels of calcium, phosphate, PTH, and alkaline phosphatase activity at least
once in adults with GFRo45ml/min/1.73 m2 (GFR categories G3b-G5) in order to determine baseline values
and inform prediction equations if used. (1C)
3.3.2: We suggest not to perform bone mineral density testing routinely in those with eGFR o45ml/min/1.73 m2
(GFR categories G3b-G5), as information may be misleading or unhelpful. (2B)
3.3.3: In people with GFRo45ml/min/1.73 m2 (GFR categories G3b-G5), we suggest maintaining serum phosphate
concentrations in the normal range according to local laboratory reference values. (2C)
3.3.4: In people with GFR o45ml/min/1.73 m2 (GFR categories G3b-G5) the optimal PTH level is not known.
We suggest that people with levels of intact PTH above the upper normal limit of the assay are first evaluated
for hyperphosphatemia, hypocalcemia, and vitamin D deficiency. (2C)
Vitamin D supplementation and bisphosphonates in people with CKD
3.3.5: We suggest not to routinely prescribe vitamin D supplements or vitamin D analogs, in the absence of suspected or
documented deficiency, to suppress elevated PTH concentrations in people with CKD not on dialysis. (2B)
3.3.6: We suggest not to prescribe bisphosphonate treatment in people with GFRo30ml/min/1.73 m2 (GFR categories
G4-G5) without a strong clinical rationale. (2B)
3.4: ACIDOSIS
3.4.1: We suggest that in people with CKD and serum bicarbonate concentrations o22mmol/l treatment with oral
bicarbonate supplementation be given to maintain serum bicarbonate within the normal range, unless
contraindicated. (2B)
Chapter 4: Other complications of CKD: CVD,
medication dosage, patient safety, infections,
hospitalizations, and caveats for investigating
complications of CKD
4.1:CKD AND CVD
4.1.1: We recommend that all people with CKD be considered at increased risk for cardiovascular disease. (1A)
4.1.2: We recommend that the level of care for ischemic heart disease offered to people with CKD should not be
prejudiced by their CKD. (1A)
4.1.3: We suggest that adults with CKD at risk for atherosclerotic events be offered treatment with antiplatelet agents
unless there is an increased bleeding risk that needs to be balanced against the possible cardiovascular benefits. (2B)
4.1.4: We suggest that the level of care for heart failure offered to people with CKD should be the same as is offered to
those without CKD. (2A)
4.1.5: In people with CKD and heart failure, any escalation in therapy and/or clinical deterioration should prompt
monitoring of eGFR and serum potassium concentration. (Not Graded)
4.2: CAVEATS WHEN INTERPRETING TESTS FOR CVD IN PEOPLE WITH CKD
BNP/N-terminal-proBNP (NT-proBNP)
4.2.1: In people with GFRo60ml/min/1.73 m2 (GFR categories G3a-G5), we recommend that serum concentrations
of BNP/NT-proBNP be interpreted with caution and in relation to GFR with respect to diagnosis of heart
failure and assessment of volume status. (1B)
Troponins
4.2.2: In people with GFRo60ml/min/1.73 m2 (GFR categories G3a-G5), we recommend that serum concentrations
of troponin be interpreted with caution with respect to diagnosis of acute coronary syndrome. (1B)
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Non-invasive testing
4.2.3: We recommend that people with CKD presenting with chest pain should be investigated for underlying
cardiac disease and other disorders according to the same local practice for people without CKD (and
subsequent treatment should be initiated similarly). (1B)
4.2.4: We suggest that clinicians are familiar with the limitations of non-invasive cardiac tests (e.g., exercise
electrocardiography [ECG], nuclear imaging, echocardiography, etc.) in adults with CKD and interpret the
results accordingly. (2B)
4.3: CKD AND PERIPHERAL ARTERIAL DISEASE
4.3.1: We recommend that adults with CKD be regularly examined for signs of peripheral arterial disease and be
considered for usual approaches to therapy. (1B)
4.3.2: We suggest that adults with CKD and diabetes are offered regular podiatric assessment. (2A)
4.4: MEDICATION MANAGEMENT AND PATIENT SAFETY IN CKD
4.4.1: We recommend that prescribers should take GFR into account when drug dosing. (1A)
4.4.2: Where precision is required for dosing (due to narrow therapeutic or toxic range) and/or estimates may be unreliable
(e.g., due to low muscle mass), we recommend methods based upon cystatin C or direct measurement of GFR. (1C)
4.4.3: We recommend temporary discontinuation of potentially nephrotoxic and renally excreted drugs in people with a
GFR o60ml/min/1.73 m2 (GFR categories G3a-G5) who have serious intercurrent illness that increases the risk of
AKI. These agents include, but are not limited to: RAAS blockers (including ACE-Is, ARBs, aldosterone inhibitors,
direct renin inhibitors), diuretics, NSAIDs, metformin, lithium, and digoxin. (1C)
4.4.4: We recommend that adults with CKD seek medical or pharmacist advice before using over-the-counter medicines or
nutritional protein supplements. (1B)
4.4.5: We recommend not using herbal remedies in people with CKD. (1B)
4.4.6: We recommend that metformin be continued in people with GFR Z45ml/min/1.73 m2 (GFR categories G1-G3a);
its use should be reviewed in those with GFR 30–44ml/min/1.73 m2 (GFR category G3b); and it should be
discontinued in people with GFR o30ml/min/1.73 m2 (GFR categories G4-G5). (1C)
4.4.7: We recommend that all people taking potentially nephrotoxic agents such as lithium and calcineurin
inhibitors should have their GFR, electrolytes and drug levels regularly monitored. (1A)
4.4.8: People with CKD should not be denied therapies for other conditions such as cancer but there should be
appropriate dose adjustment of cytotoxic drugs according to knowledge of GFR. (Not Graded)
4.5: IMAGING STUDIES
4.5.1: Balance the risk of acute impairment in kidney function due to contrast agent use against the diagnostic value
and therapeutic implications of the investigation. (Not Graded)
Radiocontrast
4.5.2: We recommend that all people with GFR o60ml/min/1.73 m2 (GFR categories G3a-G5) undergoing elective
investigation involving the intravascular administration of iodinated radiocontrast media should be managed
according to the KDIGO Clinical Practice Guideline for AKI including:
K Avoidance of high osmolar agents (1B);
K Use of lowest possible radiocontrast dose (Not Graded);
K Withdrawal of potentially nephrotoxic agents before and after the procedure (1C);
K Adequate hydration with saline before, during, and after the procedure (1A);
K Measurement of GFR 48–96 hours after the procedure (1C).
Gadolinium-based contrast media
4.5.3: We recommend not using gadolinium-containing contrast media in people with GFR o15ml/min/1.73 m2
(GFR category G5) unless there is no alternative appropriate test. (1B)
4.5.4: We suggest that people with a GFR o30ml/min/1.73 m2 (GFR categories G4-G5) who require gadolinium-
containing contrast media are preferentially offered a macrocyclic chelate preparation. (2B)
Bowel preparation
4.5.5: We recommend not to use oral phosphate-containing bowel preparations in people with a GFR o60ml/min/
1.73 m2 (GFR categories G3a-G5) or in those known to be at risk of phosphate nephropathy. (1A)
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4.6: CKD AND RISKS FOR INFECTIONS, AKI, HOSPITALIZATIONS, AND MORTALITY
CKD and risk of infections
4.6.1: We recommend that all adults with CKD are offered annual vaccination with influenza vaccine, unless
contraindicated. (1B)
4.6.2: We recommend that all adults with eGFRo30ml/min/1.73 m2 (GFR categories G4-G5) and those at high risk
of pneumococcal infection (e.g., nephrotic syndrome, diabetes, or those receiving immunosuppression) receive
vaccination with polyvalent pneumococcal vaccine unless contraindicated. (1B)
4.6.3: We recommend that all adults with CKD who have received pneumococcal vaccination are offered
revaccination within 5 years. (1B)
4.6.4: We recommend that all adults who are at high risk of progression of CKD and have GFRo30ml/min/1.73 m2
(GFR categories G4-G5) be immunized against hepatitis B and the response confirmed by appropriate
serological testing. (1B)
4.6.5: Consideration of live vaccine should include an appreciation of the patient’s immune status and should be in
line with recommendations from official or governmental bodies. (Not Graded)
4.6.6: Pediatric immunization schedules should be followed according to official international and regional
recommedations for children with CKD. (Not Graded)
CKD and risk of AKI
4.6.7: We recommend that all people with CKD are considered to be at increased risk of AKI. (1A)
4.6.7.1: In people with CKD, the recommendations detailed in the KDIGO AKI Guideline should be followed
for management of those at risk of AKI during intercurrent illness, or when undergoing investigation
and procedures that are likely to increase the risk of AKI. (Not Graded)
CKD and risk of hospitalization and mortality
4.6.8: CKD disease management programs should be developed in order to optimize the community management of
people with CKD and reduce the risk of hospital admission. (Not Graded)
4.6.9: Interventions to reduce hospitalization and mortality for people with CKD should pay close attention to the
management of associated comorbid conditions and cardiovascular disease in particular. (Not Graded)
Chapter 5: Referral to specialists and models of care
5.1: REFERRAL TO SPECIALIST SERVICES
5.1.1: We recommend referral to specialist kidney care services for people with CKD in the following circumstances (1B):
K AKI or abrupt sustained fall in GFR;
K GFR o30ml/min/1.73 m2 (GFR categories G4-G5)*;
K a consistent finding of significant albuminuria (ACR Z300mg/g [Z30mg/mmol] or AER Z300mg/
24 hours, approximately equivalent to PCR Z500mg/g [Z50mg/mmol] or PER Z500mg/24 hours);
K progression of CKD (see Recommendation 2.1.3 for definition);
K urinary red cell casts, RBC 420 per high power field sustained and not readily explained;
K CKD and hypertension refractory to treatment with 4 or more antihypertensive agents;
K persistent abnormalities of serum potassium;
K recurrent or extensive nephrolithiasis;
K hereditary kidney disease.
5.1.2: We recommend timely referral for planning renal replacement therapy (RRT) in people with progressive CKD
in whom the risk of kidney failure within 1 year is 10–20% or higherw, as determined by validated risk
prediction tools. (1B)
*If this is a stable isolated finding, formal referral (i.e., formal consultation and ongoing care management) may not be necessary and advice
from specialist services may be all that is required to facilitate best care for the patients. This will be health-care system dependent.
wThe aim is to avoid late referral, defined here as referral to specialist services less than 1 year before start of RRT.
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5.2: CARE OF THE PATIENT WITH PROGRESSIVE CKD
5.2.1: We suggest that people with progressive CKD should be managed in a multidisciplinary care setting. (2B)
5.2.2: The multidisciplinary team should include or have access to dietary counseling, education and counseling
about different RRT modalities, transplant options, vascular access surgery, and ethical, psychological, and
social care. (Not Graded)
5.3: TIMING THE INITIATION OF RRT
5.3.1: We suggest that dialysis be initiated when one or more of the following are present: symptoms or signs
attributable to kidney failure (serositis, acid-base or electrolyte abnormalities, pruritus); inability to control
volume status or blood pressure; a progressive deterioration in nutritional status refractory to dietary
intervention; or cognitive impairment. This often but not invariably occurs in the GFR range between 5 and
10ml/min/1.73 m2. (2B)
5.3.2: Living donor preemptive renal transplantation in adults should be considered when the GFR iso20ml/min/
1.73 m2, and there is evidence of progressive and irreversible CKD over the preceding 6–12 months.
(Not Graded)
5.4: STRUCTURE AND PROCESS OF COMPREHENSIVE CONSERVATIVE MANAGEMENT
5.4.1: Conservative management should be an option in people who choose not to pursue RRT and this should be
supported by a comprehensive management program. (Not Graded)
5.4.2: All CKD programs and care providers should be able to deliver advance care planning for people with
a recognized need for end-of-life care, including those people undergoing conservative kidney care. (Not
Graded)
5.4.3: Coordinated end-of-life care should be available to people and families through either primary care or
specialist care as local circumstances dictate. (Not Graded)
5.4.4: The comprehensive conservative management program should include protocols for symptom and pain
management, psychological care, spiritual care, and culturally sensitive care for the dying patient and their
family (whether at home, in a hospice or a hospital setting), followed by the provision of culturally
appropriate bereavement support. (Not Graded)




































G1 Normal or high ≥90 Monitor Refer*
G2 Mildly decreased 60–89 Monitor Refer*
G3a 45–59 Monitor Monitor Refer
G3b 30–44 Monitor Monitor Refer
G4 Severely decreased 15–29 Refer* Refer* Refer
G5 Kidney failure <15 Refer Refer Refer










Referral decision making by GFR and albuminuria. *Referring clinicians may wish to discuss with their nephrology service depending on
local arrangements regarding monitoring or referring.
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